Nataliya Brytska1, Ho-Seong Han1, Ahmed Shehta1, Yoo-Seok Yoon1, Jai Young Cho1, YoungRok Choi1. 1. 1 Department of Hepatobiliary and Pancreatic Surgery, State Institution "Zaycev V.T. Institute of General and Urgent Surgery of National Academy of Medical Sciences of Ukraine", Ukraine ; 2 Department of General Surgery, Seoul National University Bundang Hospital, Seoul National University, Seoul, South Korea ; 3 Gastroenterology Surgical Centre, Department of Surgery, Mansoura University, Mansoura, Egypt.
Abstract
BACKGROUND: The aim of this study was to evaluate the clinical and oncological outcomes after laparoscopic liver resection (LLR) in patients with hepatitis B and C virus-related hepatocellular carcinoma (HCC) with Child B or C cirrhosis. METHODS: Between January 2004 and December 2013, LLR was performed in 232 patients with HCC. Of these, 141 patients also had pathologically proven cirrhosis. Sixteen patients with hepatitis B and C virus-related HCC with Child B or C cirrhosis were included in the study. Thirteen (81.3%) patients had Child B disease and three (18.8%) patients had Child C disease. RESULTS: The median operation time was 215 min, the median estimated blood loss was 350 mL, and the median hospital stay was eight days. Three patients (18.8%) experienced complications after surgery. There was no postoperative mortality or reoperation. The mean follow-up period was 51.6 months. HCC recurred in eight (50%) patients: seven intrahepatic recurrences and one extrahepatic recurrence. The treatments for recurrence were laparoscopic reoperation in one (6.3%) patient, trans-catheter arterial chemo-embolization (TACE) in one (6.3%) patient, radiofrequency ablation (RFA) in one (6.3%) patient, and combined TACE and RFA in four (25%) patients. The five-year postoperative overall survival (OS) and disease-free survival (DFS) were 84.4% and 41.7%, respectively. CONCLUSIONS: This study demonstrates that LLR can be safely used in patients with hepatitis B and C virus-related HCC and Child B or C cirrhosis, with acceptable survival outcomes.
BACKGROUND: The aim of this study was to evaluate the clinical and oncological outcomes after laparoscopic liver resection (LLR) in patients with hepatitis B and C virus-related hepatocellular carcinoma (HCC) with Child B or C cirrhosis. METHODS: Between January 2004 and December 2013, LLR was performed in 232 patients with HCC. Of these, 141 patients also had pathologically proven cirrhosis. Sixteen patients with hepatitis B and C virus-related HCC with Child B or C cirrhosis were included in the study. Thirteen (81.3%) patients had Child B disease and three (18.8%) patients had ChildC disease. RESULTS: The median operation time was 215 min, the median estimated blood loss was 350 mL, and the median hospital stay was eight days. Three patients (18.8%) experienced complications after surgery. There was no postoperative mortality or reoperation. The mean follow-up period was 51.6 months. HCC recurred in eight (50%) patients: seven intrahepatic recurrences and one extrahepatic recurrence. The treatments for recurrence were laparoscopic reoperation in one (6.3%) patient, trans-catheter arterial chemo-embolization (TACE) in one (6.3%) patient, radiofrequency ablation (RFA) in one (6.3%) patient, and combined TACE and RFA in four (25%) patients. The five-year postoperative overall survival (OS) and disease-free survival (DFS) were 84.4% and 41.7%, respectively. CONCLUSIONS: This study demonstrates that LLR can be safely used in patients with hepatitis B and C virus-related HCC and Child B or C cirrhosis, with acceptable survival outcomes.
Authors: Nuh N Rahbari; O James Garden; Robert Padbury; Mark Brooke-Smith; Michael Crawford; Rene Adam; Moritz Koch; Masatoshi Makuuchi; Ronald P Dematteo; Christopher Christophi; Simon Banting; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yukihiro Yokoyama; Sheung Tat Fan; Yuji Nimura; Joan Figueras; Lorenzo Capussotti; Markus W Büchler; Jürgen Weitz Journal: Surgery Date: 2011-01-14 Impact factor: 3.982
Authors: Jun-Jie Xiong; Kiran Altaf; Muhammad A Javed; Wei Huang; Rajarshi Mukherjee; Gang Mai; Robert Sutton; Xu-Bao Liu; Wei-Ming Hu Journal: World J Gastroenterol Date: 2012-12-07 Impact factor: 5.742
Authors: S Truant; A F Bouras; M Hebbar; E Boleslawski; G Fromont; S Dharancy; E Leteurtre; P Zerbib; F R Pruvot Journal: Surg Endosc Date: 2011-06-18 Impact factor: 4.584
Authors: Giulio Belli; Luigi Cioffi; Corrado Fantini; Alberto D'Agostino; Gianluca Russo; Paolo Limongelli; Andrea Belli Journal: Surg Endosc Date: 2009-03-10 Impact factor: 4.584
Authors: Tan To Cheung; Ho-Seong Han; Wong Hoi She; Kuo-Hsin Chen; Pierce K H Chow; Boon Koon Yoong; Kit Fai Lee; Shoji Kubo; Chung Ngai Tang; Go Wakabayashi Journal: Liver Cancer Date: 2017-12-09 Impact factor: 11.740